Pacira BioSciences: Business Model, SWOT Analysis, and Competitors 2026

Pacira BioSciences, Inc. stands as a leading company in Healthcare. Generating $726.41 million in annual revenue (growing 5.1% year-over-year) and carrying a market capitalization of $983.47 million, the company has cemented its position as a foundational player in the global Drug Manufacturers - Specialty & Generic landscape. Under the leadership of its leadership team, Pacira BioSciences, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Pacira BioSciences, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Pacira BioSciences, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Pacira BioSciences, Inc.'s position in the Drug Manufacturers - Specialty & Generic market today.

What You Will Learn

1. How Pacira BioSciences, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Pacira BioSciences, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Pacira BioSciences, Inc.'s main competitors are and how the company compares on key financial metrics
4. Pacira BioSciences, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Pacira BioSciences, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $726.41 million annual revenue (TTM), +5.1% YoY
• Market Cap: $983.47 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 63.2%, operating margin -1.2%, net margin 1.0%
• Free Cash Flow: $108.56 million
• Return on Equity: 1.0% — reflects current investment phase
• Employees: 825 worldwide

Who Owns Pacira BioSciences, Inc.?

Pacira BioSciences, Inc. is publicly traded on the NMS under the ticker symbol PCRX. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Pacira BioSciences, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Pacira BioSciences, Inc. has approximately 0.04 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $22.86 per share as of early 2026.

Pacira BioSciences, Inc.'s Mission Statement

Pacira BioSciences, Inc.'s strategic mission is aligned with its core business activities in the Drug Manufacturers - Specialty & Generic sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Pacira BioSciences, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Pacira BioSciences, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Pacira BioSciences, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Pacira BioSciences, Inc. Make Money?

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medici

Pacira BioSciences, Inc.'s business model is built around delivering value to its customers in the Drug Manufacturers - Specialty & Generic segment of the Healthcare sector. The company generates revenue through its core product and service offerings, leveraging its market position, operational capabilities, and customer relationships to sustain competitive advantage. Like most companies in Drug Manufacturers - Specialty & Generic, Pacira BioSciences, Inc.'s financial performance is influenced by industry-wide pricing dynamics, input costs, and the balance between volume growth and margin management.

Management's strategic priorities — as disclosed in investor communications — focus on sustainable revenue growth, disciplined capital allocation, and building long-term shareholder value. Investors should review Pacira BioSciences, Inc.'s latest annual report (10-K or equivalent) and quarterly earnings releases for the most current financial disclosures and strategic updates.

Pacira BioSciences, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how Pacira BioSciences, Inc. creates, delivers, and captures value.

Key Partners: Pacira BioSciences, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Drug Manufacturers - Specialty & Generic sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Pacira BioSciences, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Pacira BioSciences, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (825 employees), proprietary technology, and financial resources ($238.42M in cash).

Value Propositions: Pacira BioSciences, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Drug Manufacturers - Specialty & Generic market.

Customer Relationships: Pacira BioSciences, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Pacira BioSciences, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Pacira BioSciences, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Pacira BioSciences, Inc.'s major costs include cost of goods sold (36.8% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 101.2% of revenue.

Revenue Streams: Pacira BioSciences, Inc. generates revenue through its core product and service offerings.

Pacira BioSciences, Inc. Competitors

Pacira BioSciences, Inc. competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Drug Manufacturers - Specialty & Generic segment of the Healthcare sector.

Pacira BioSciences, Inc. SWOT Analysis

A SWOT analysis examines Pacira BioSciences, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Pacira BioSciences, Inc.'s gross margin of 63.2% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -1.2% demonstrates disciplined cost management even at scale.

Weaknesses

• Leverage Risk: Pacira BioSciences, Inc.'s debt-to-equity ratio of 60.3 indicates meaningful financial leverage. Total debt stands at $418.20M against $238.42M in cash and equivalents.
• Thin Profit Margins: A net profit margin of 1.0% leaves limited buffer against revenue fluctuations or cost increases. Any significant market downturn could quickly pressure profitability.

Opportunities

• Total Addressable Market: Pacira BioSciences, Inc. operates in the Drug Manufacturers - Specialty & Generic segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Pacira BioSciences, Inc.'s products and services.
• Strategic Acquisitions: With $238.42M in cash and strong free cash flow generation, Pacira BioSciences, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Pacira BioSciences, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Pacira BioSciences, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Pacira BioSciences, Inc. enters 2026 as a leading company in Healthcare, backed by $726.41 million in annual revenue and a 1.0% net profit margin. The company's 63.2% gross margins and $108.56 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Pacira BioSciences, Inc.'s core markets.

For investors, Pacira BioSciences, Inc.'s 48.6x trailing P/E and 6.5x forward P/E reflect the market's expectations for stable earnings. Analysts and investors should watch quarterly earnings releases, management commentary on comparable sales growth, margin trends, and capital allocation for signals of how the investment thesis is progressing.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Pacira BioSciences, SEC EDGAR – Pacira BioSciences Filings, and Pacira BioSciences's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. 1. What is Pacira BioSciences Inc. known for?

Pacira BioSciences, Inc. generated $726.41 million in annual revenue with a 1.0% net profit margin as of the latest reporting period. The company operates in the Drug Manufacturers - Specialty & Generic sector. For the most current information, consult Pacira BioSciences, Inc.'s investor relations page.

2. 2. What is the significance of EXPAREL?

Pacira BioSciences, Inc. generated $726.41 million in annual revenue with a 1.0% net profit margin as of the latest reporting period. The company operates in the Drug Manufacturers - Specialty & Generic sector. For the most current information, consult Pacira BioSciences, Inc.'s investor relations page.

3. 3. How does Pacira's business model work?

Pacira BioSciences, Inc. generates $726.41 million in annual revenue (TTM) with a 63.2% gross margin, growing 5.1% year-over-year. The company's revenue model is described in detail in the business model section above.

4. 4. Who are Pacira's main competitors?

Pacira BioSciences, Inc. competes in the Drug Manufacturers - Specialty & Generic segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Drug Manufacturers - Specialty & Generic center on product differentiation, pricing strategy, and distribution scale.

5. 5. What trends should be watched in the biopharmaceutical industry?

Pacira BioSciences, Inc. generated $726.41 million in annual revenue with a 1.0% net profit margin as of the latest reporting period. The company operates in the Drug Manufacturers - Specialty & Generic sector. For the most current information, consult Pacira BioSciences, Inc.'s investor relations page.

6. 6. What are the potential risks for Pacira?

Pacira BioSciences, Inc. faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Pacira BioSciences, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a r Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Pacira BioSciences, Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.